Rodriguez García, EvaBarrios Barrera, ClaraSoler, María José2018-05-082018-05-082017Rodriguez E, Barrios C, Soler MJ. Should eculizumab be discontinued in patients with atypical hemolytic uremic syndrome?. Clin Kidney J. 2017 Jun;10(3):320-322. DOI: 10.1093/ckj/sfx0242048-8505http://hdl.handle.net/10230/34580Atypical hemolytic uremic syndrome (aHUS) is a life-threatening disorder for which prompt diagnosis and eculizumab treatment is indicated. The time for relapse and patients at risk for relapse after eculizumab discontinuation are unknown. While some authors believe there is no clinical evidence supporting eculizumab discontinuation, which may be associated with high collateral risks such as loss of renal function, other authors believe that the drug can be safely discontinued with close patient monitoring. In this editorial, we update the pros and cons for eculizumab discontinuation in aHUS.application/pdfeng© The Author 2017. Published by Oxford University Press on behalf of ERA-EDTA. This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.comRonyons -- Malalties -- Tractamentinfo:eu-repo/semantics/articlehttp://dx.doi.org/10.1093/ckj/sfx024Eculizumabinfo:eu-repo/semantics/openAccess